Lixian Dong
About Lixian Dong
Lixian Dong is the Medical Director and Medical Safety Assessment Physician at Bristol-Myers Squibb, with extensive experience in drug safety and pharmacovigilance.
Title
Lixian Dong currently holds the role of Medical Director, Medical Safety Assessment Physician at Bristol-Myers Squibb.
Company
Lixian Dong works at Bristol-Myers Squibb, a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Education and Expertise
Lixian Dong achieved a Doctor of Philosophy (Ph.D.) in Physiology from Rosalind Franklin University of Medicine and Science, investing five years in her studies from 2001 to 2006. Prior to that, Dong earned her Doctor of Medicine (MD) from Qingdao University Medical School, where she studied Medicine from 1994 to 1999.
Professional Background
Lixian Dong has held various key positions in the medical safety and pharmacovigilance field. She served as Global Safety Physician at AstraZeneca from 2014 to 2017. Prior to that, she worked as a Pharmacovigilance Scientist at MedImmune from 2013 to 2014. Between 2010 and 2012, she was a Drug Safety and Pharmacovigilance Scientist at NIH & TRI. She commenced her professional journey as a Research Fellow at Children's National Medical Center from 2008 to 2010.
Current Responsibilities
At Bristol-Myers Squibb, Lixian Dong chairs the Medical Surveillance Team. She leads global safety activities for an immunoscience product, including safety activities related to regulatory filings, signal detection, and safety assessment. Dong also manages risk management, health authority responses, label updates, and aggregate reports.